Skip to content
Homepage
Author:
UroGen Pharma Ltd.
Posted Date:
March 6, 2026
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd.
March 6, 2026
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
UroGen Pharma Ltd.
March 2, 2026
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
UroGen Pharma Ltd.
March 2, 2026
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
UroGen Pharma Ltd.
February 27, 2026
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
UroGen Pharma Ltd.
February 24, 2026
UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026
UroGen Pharma Ltd.
February 23, 2026
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
UroGen Pharma Ltd.
February 10, 2026
Prev
1
2
3
